Lipidoid nanoparticles for siRNA delivery to the intestinal epithelium: In vitro investigations in a CACO-2 model

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Ball, Rebecca L ^a   Knapp, Christopher M ^a   Whitehead, Kathryn A ^a  

^a CARNEGIE MELLON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LIPIDOID NANOPARTICLE; MESSENGER RNA; NANOPARTICLE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CACO 2 CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; ENTEROPATHY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE EPITHELIUM; MTT ASSAY; NONVIRAL GENE DELIVERY SYSTEM; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; WESTERN BLOTTING; CACO-2 CELL LINE; DRUG EFFECTS; GENETICS; INTESTINE MUCOSA; METABOLISM; PROCEDURES;

CACO-2 CELLS; GENE SILENCING; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE (PHOSPHORYLATING); HUMANS; INTESTINAL MUCOSA; NANOPARTICLES; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84941287130     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133154     Document Type: Article

References (48)

1. Lautenschläger C, Schmidt C, Fischer D, Stallmach A. Drug delivery strategies in the therapy of inflammatory bowel disease. Adv Drug Deliv Rev. 2014; 71(2013):58-76.
2. Jemal A, Freddie F, Center M, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2):1, 33-64.
3. Talaei F, Atyabi F, Azhdarzadeh M, Dinarvand R, Saadatzadeh A. Overcoming therapeutic obstacles in inflammatory bowel diseases: A comprehensive review on novel drug delivery strategies. Eur J Pharm Sci. Elsevier B.V.; 2013; 49(4):712-22.
4. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011. p. 307-17.
5. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011; 474:298-306. doi:10.1038/nature10208PMID: 21677746.
6. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011; 6:479-507. doi:10.1146/annurev-pathol-011110-130235 PMID: 21090969.
7. Ponder A, Long MD. A clinical review of recent findings in the epidemiology of inflammatory bowel disease. Clin Epidemiol. 2013; 5:237-47. doi:10.2147/CLEP.S33961 PMID: 23922506.
8. Suzuki M, Nagaishi T, Yamazaki M, Onizawa M, Watabe T, Sakamaki Y, et al. Myosin light chain kinase expression induced via tumor necrosis factor receptor 2 signaling in the epithelial cells regulates the development of colitis-associated carcinogenesis. PLoS One. 2014; 9(2).
9. Blair S a, Kane S V, Clayburgh DR, Turner JR. Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Lab Investig. 2006; 86:191-201. PMID: 16402035.
10. Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012; 149:1192-205. doi:10.1016/j.cell.2012.05.012 PMID: 22682243.
11. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: Advances in siRNA delivery. Nat Rev Drug Discov. 2009 Feb 1; 8(2):129-38. doi:10.1038/nrd2742PMID: 19180106.
12. Collnot EM, Ali H, Lehr CM. Nano- And microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J Control Release. 2012; 161(2):235-46. doi:10.1016/j.jconrel.2012.01.028 PMID: 22306429.
13. Tahara K, Samura S, Tsuji K, Yamamoto H, Tsukada Y, Bando Y, et al. Oral nuclear factor-κB decoy oligonucleotides delivery system with chitosan modified poly(d, l-lactide-co-glycolide) nanospheres for inflammatory bowel disease. Biomaterials. 2011; 32(3):870-8. doi:10.1016/j.biomaterials.2010.09.034 PMID: 20934748.
14. Mladenovska K, Raicki RS, Janevik EI, Ristoski T, Pavlova MJ, Kavrakovski Z, et al. Colon-specific delivery of 5-aminosalicylic acid from chitosan-Ca-alginate microparticles. Int J Pharm. 2007; 342:124- 36. PMID: 17590293.
15. Wilson DS, Dalmasso G, Wang L, Sitaraman S V, Merlin D, Murthy N. Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater. 2010; 9(11):923-8doi:10.1038/nmat2859PMID: 20935658.
16. He C, Yin L, Tang C, Yin C. Multifunctional polymeric nanoparticles for oral delivery of TNF-α siRNA to macrophages. Biomaterials. 2013; 34(11):2843-54. doi:10.1016/j.biomaterials.2013.01.033 PMID: 23347838.
17. Kriegel C, Amiji M. Oral TNF-α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. J Control Release. 2011; 150(1):77-86. doi:10.1016/j.jconrel.2010.10.002PMID: 20959130.
18. He F, Peng J, Deng XL, Yang LF, Camara AD, Omran A, et al. Mechanisms of tumor necrosis factor-α- induced leaks in intestine epithelial barrier. Cytokine. 2012; 59(2):264-72. doi: 10.1016/j.cyto.2012.04.008 PMID: 22583690.
19. Nielsen OH, Ainsworth MA. Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease. N Engl J Med. 2013; 369:754-62. doi:10.1056/NEJMct1209614 PMID: 23964937.
20. Nielsen OH, Seidelin JB, Munck LK, Rogler G. Use of biological molecules in the treatment of inflammatory bowel disease. J Intern Med. 2011; 270:15-28. doi:10.1111/j.1365-2796.2011.02344.x PMID: 21241384.
21. Guo J, O'Mahony AM, Cheng WP, O'Driscoll CM. Amphiphilic polyallylamine based polymeric micelles for siRNA delivery to the gastrointestinal tract: In vitro investigations. Int J Pharm. 2013; 447(1-2):150- 7. doi:10.1016/j.ijpharm.2013.02.050 PMID: 23467082.
22. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB. Advances in Brief Small Interfering RNAs Directed against β-Catenin Inhibit the in Vitro and in Vivo Growth of Colon Cancer Cells. Clin Cancer Res. 2003; 9(April):1291-300.
23. Burnett JC, Rossi JJ. RNA-Based Therapeutics: Current Progress and Future Prospects. Chem Biol. 2012; 19(1):60-71. doi:10.1016/j.chembiol.2011.12.008 PMID: 22284355.
24. Zhang YG, Wu S, Xia Y, Sun J. Salmonella Infection Upregulates the Leaky Protein Claudin-2 in Intestinal Epithelial Cells. PLoS One. 2013; 8(3):1-11.
25. Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol. 2008; 26(5):561-9. doi:10.1038/nbt1402 PMID: 18438401.
26. Whitehead KA, Dorkin JR, Vegas AJ, Chang PH, Veiseh O, Matthews J, et al. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat Commun. 2014; 5:4277. doi:10.1038/ncomms5277 PMID: 24969323.
27. Siegwart DJ, Whitehead KA, Nuhn L, Sahay G, Cheng H, Jiang S, et al. Combinatorial synthesis of chemically diverse core-shell nanoparticles for intracellular delivery. Proc Natl Acad Sci U S A. 2011; 108:12996-3001. doi:10.1073/pnas.1106379108 PMID: 21784981.
28. Walsh CL, Nguyen J, Tiffany MR, Szoka FC. Synthesis, characterization, and evaluation of ionizable lysine-based lipids for siRNA delivery. Bioconjug Chem. 2013; 24:36-43. doi:10.1021/bc300346h PMID: 23176544.
29. He C, Zhuang X, Tang Z, Tian H, Chen X. Stimuli-sensitive synthetic polypeptide-based materials for drug and gene delivery. Adv Healthc Mater. 2012; 1:48-78. doi:10.1002/adhm.201100008PMID: 23184687.
30. Whitehead KA, Matthews J, Chang PH, Niroui F, Dorkin JR, Severgnini M, et al. In vitro-In vivo translation of lipid nanoparticles for hepatocellular siRNA delivery. ACS Nano. 2012; 6(8):6922-9. doi:10.1021/nn301922x PMID: 22770391.
31. Sambuy Y, De Angelis I, Ranaldi G, Scarino ML, Stammati A, Zucco F. The Caco-2 cell line as a model of the intestinal barrier: Influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol Toxicol. 2005; 21(1):1-26. PMID: 15868485.
32. Press B, Di Grandi D. Permeability for intestinal absorption: Caco-2 assay and related issues. Curr Drug Metab. 2008; 9(C):893-900.
33. Pinto M, Robine-Leon S, Appay M-D, Kedinger M, Triadou N, Dussaulx E, et al. Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol Cell. 1983; 47 (323):323-30.
34. Sirover MA. New insights into an old protein: The functional diversity of mammalian glyceraldehyde-3- phosphate dehydrogenase. Biochim Biophys Acta. 1999; 1432:159-84. PMID: 10407139.
35. Sirover MA. On the functional diversity of glyceraldehyde-3-phosphate dehydrogenase: biochemical mechanisms and regulatory control. Biochim Biophys Acta. 2011; 1810(8):741-51doi:10.1016/j.bbagen.2011.05.010 PMID: 21640161.
36. Whitehead KA, Karr N, Mitragotri S. Safe and effective permeation enhancers for oral drug delivery. Pharm Res. 2008; 25:1782-8. PMID: 18058001.
37. Varkouhi AK, Scholte M, Storm G, Haisma HJ. Endosomal escape pathways for delivery of biologicals. J Control Release. 2011; 151(3):220-8. doi:10.1016/j.jconrel.2010.11.004 PMID: 21078351.
38. Reineke JJ, Cho DY, Dingle Y-T, Morello AP, Jacob J, Thanos CG, et al. Unique insights into the intestinal absorption, transit, and subsequent biodistribution of polymer-derived microspheres. Proc Natl Acad Sci U S A. 2013; 110:13803-8. doi:10.1073/pnas.1305882110PMID: 23922388.
39. Yoncheva K, Centelles MN, Irache JM. Development of bioadhesive amino-pegylated poly(anhydride) nanoparticles designed for oral DNA delivery. J Microencapsul. 2008 Oct 8; 25(2):82-9. doi:10.1080/02652040701776083 PMID: 18246486.
40. Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release. 2006; 114:100-9. PMID: 16831482.
41. Creamer B, Shorter RG, Bamforth J. The turnover and shedding of epithelial cells. I. The turnover in the gastro-intestinal tract. Gut. 1961; 2:110-8. PMID: 13696345.
42. Franch H a, Sooparb S, Du J. A mechanism regulating proteolysis of specific proteins during renal tubular cell growth. J Biol Chem. 2001; 276(22):19126-31. PMID: 11262416.
43. Serafini EP, Kirk AP, Chambers TJ. Rate and pattern of epithelial cell proliferation in ulcerative colitis. Gut. 1981; 22:648-52. PMID: 7286781.
44. Gottlieb TA, Ivanov IE, Adesnik M, Sabatini DD. Actin filaments play a critical role in endocytosis at the apical but not the basolateral surface of polarized epithelial cells. J Cell Biol. 1993; 120(3):695-710. PMID: 8381123.
45. Camilleri M, Lasch K, Zhou W. Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. AJP Gastrointest Liver Physiol. 2012; 303:G775-85.
46. Benson K, Cramer S, Galla H-J. Impedance-based cell monitoring: barrier properties and beyond. Fluids Barriers CNS. 2013; 10:1-11. doi:10.1186/2045-8118-10-5PMID: 23305242.
47. Shen L, Weber CR, Raleigh DR, Yu D, Turner JR. Tight junction pore and leak pathways: A dynamic duo. Annu Rev Physiol. 2011; 73:283-309. doi:10.1146/annurev-physiol-012110-142150PMID: 20936941.
48. Mahon KP, Love KT, Whitehead KA, Qin J, Akinc A, Leshchiner E, et al. Combinatorial approach to determine functional group effects on lipidoid-mediated siRNA delivery. Bioconjug Chem. 2010; 21 (8):1448-54. doi:10.1021/bc100041r PMID: 20715849.